secwatch.observer — SEC 8-K summary
======================================

Issuer:     HERON THERAPEUTICS, INC. /DE/ (HRTX)
CIK:        0000818033
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0000950170-24-091769
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Heron Therapeutics Q2 net product sales $36.0M; narrows 2024 guidance
---------------------------------------------------------------------

- Q2 net product sales $36.0M, up from $31.8M YoY; acute care franchise $6.8M, oncology $29.2M.
- ZYNRELEF VAN PDUFA goal date set for September 23, 2024; launch expected before year-end.
- 2024 guidance narrowed: adjusted operating expenses $107-111M (prev $108-116M), adjusted EBITDA ($10) to $3M (prev ($22) to $3M).
- ZYNRELEF included in proposed 2025 NOPAIN Act as a qualifying product effective April 1, 2025.
- CrossLink partnership expanding; 561 sales representatives trained to promote ZYNRELEF to orthopedic surgeons.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818033/000095017024091769/0000950170-24-091769-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818033/000095017024091769/hrtx-20240806.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-091769

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer